MBX Biosciences, Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Operating Activities | |||
| Net Income | $-87.0M | $-61.9M | $-32.6M |
| Depreciation & Amortization | — | — | — |
| Depreciation | $248.0K | $244.0K | $157.0K |
| Amortization | — | — | — |
| Stock-Based Compensation | $8.7M | $5.2M | $2.0M |
| Net Cash from Operating Activities | $-79.9M | $-54.7M | $-32.0M |
| Investing Activities | |||
| Capital Expenditures | $1.9M | $874.0K | $129.0K |
| Business Acquisitions | — | — | — |
| Net Cash from Investing Activities | $-83.7M | $-160.6M | $-30.9M |
| Financing Activities | |||
| Dividends Paid | — | — | — |
| Stock Repurchases | — | — | — |
| Net Cash from Financing Activities | $189.6M | $234.1M | $69.2M |
| Net Change in Cash | $25.9M | $18.8M | $6.3M |
| Free Cash Flow | $-81.9M | $-55.6M | $-32.1M |
The best armour of old age is a well spent life perfecting it.